Molbio Diagnostics IPO Allotment: Your Status Awaits—Check Now!
The IPO allotment for Molbio Diagnostics, one of the most eagerly awaited healthcare offerings this year, is set to conclude on August 13, 2026. The public issue, valued at INR 939.70 crore, received an overwhelming response, with bids surpassing INR 46,172 crore and over 22.18 lakh applications submitted. Retail investors reported a subscription rate of 12.96 times, while the small and big HNI categories saw even more intense competition, with subscription rates of 47.76x and 50.82x respectively. This high demand reflects the strong investor confidence in the company’s innovative molecular diagnostics technologies.
In terms of grey market sentiment, the enthusiasm surrounding the Molbio Diagnostics IPO is palpable. Early indications suggest a robust demand in the grey market, often a barometer of listing performance. With total subscriptions hitting 70.26 times, investors are keenly assessing their chances of obtaining shares, especially given the competitive ratios—approximately 1 in 11 for retail investors and around 1 in 10 for big HNIs. Such high subscription rates typically correlate with positive listing gains, indicating that investors could see attractive returns on their investments once the shares hit the market.
For Indian investors, the Molbio Diagnostics IPO represents a significant opportunity to engage with a promising segment of the healthcare industry. The impending listing on both the BSE and NSE on August 17, 2026, will be crucial for investors looking to capitalize on the company’s growth potential. Given the heightened competition and robust grey market sentiment, participants should remain vigilant, as the listing could yield beneficial outcomes for those who successfully secure allotments. With advancements in healthcare being a focal point for many investors, this IPO may pave the way for further innovation and investment interest in the sector.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)